Evaluating Treatment Options of EGFR Inhibitors

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.